HOOKIPA Pharma to Report Second Quarter 2022 Financial Results on August 11, 2022
HOOKIPA Pharma Inc. (NASDAQ: HOOK) will release its second quarter 2022 financial results and company update on August 11, 2022, prior to market opening.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
HOOKIPA Pharma Inc. (NASDAQ: HOOK) will release its second quarter 2022 financial results and company update on August 11, 2022, prior to market opening. The company, focused on immunotherapies using its proprietary arenavirus platform, aims to mobilize targeted T cells to combat serious diseases. Its pipeline includes investigational therapies for HPV16+ cancers, prostate cancer, KRAS-mutated cancers, and efforts to develop functional cures for HBV and HIV in collaboration with Gilead. No conference call is scheduled for this earnings release.
Positive
- Ongoing development of innovative immunotherapies targeting various cancers.
- Collaboration with Gilead to develop functional cures for HBV and HIV.
Negative
- None.
Details
News Market Reaction – HOOK
The recorded move for HOOK in the trading session of this news was +4.76%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK and VIENNA, Austria, Aug. 04, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus platform, today announced that it will release its second quarter 2022 financial results and Company update before the market open on Thursday, August 11, 2022.
The Company will not be conducting a conference call in conjunction with this earnings release.
About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ cell responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline includes its wholly owned investigational arenaviral immunotherapies targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers (including colorectal, pancreatic and lung), and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures for HBV and HIV in collaboration with Gilead.
Find out more about HOOKIPA online at www.hookipapharma.com.
| For further information, please contact: | |
| Media | Investors |
| Michael Szumera | Matt Beck |
| Executive Director - Communications | Executive Director - Investor Relations |
| michael.szumera@hookipapharma.com | matthew.beck@hookipapharma.com |
| +1 917 561 8905 | +1 917 209 6886 |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.